Intraperitoneal Follicular Dendritic Cell Sarcoma: Role of Chemotherapy and Bone Marrow Allotransplantation in Locally Advanced Disease? by Liberale, G. et al.
Open Access: Full open access to 
this and thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: 
Oncology
Introduction
Follicular dendritic cell sarcoma (FDCS) is a neoplastic 
proliferation of spindled to ovoid cells showing morphologic 
and phenotypic features of follicular dendritic cells and was 
firstly described by Monda in 1986.1 Only few case reports and 
retrospective series have been published.2–15 FDCS mainly 
affects head and neck lymph nodes.16 Intraperitoneal location 
of FDCS is a very uncommon discovery and is associated with 
a particularly aggressive clinical course.2,13
In this report, we present a case of advanced intraperito-
neal FDCS treated successfully with chemotherapy and bone 
marrow allotransplantation.
Case Report
A 44 year-old woman with no known previous medical his-
tory, presented with a painless periumbilical mass, associ-
ated with intermittent constipation. An abdominal computed 
tomography (CT) was performed and showed a homogeneous 
enhancing mass in the lesser omentum, 5 cm in diameter 
and located in front of the pancreas. Another subhepatic 
heterogeneous enhancing mass of 5.9 × 8.6 × 7 cm was also 
detected and a retroperitoneal lymph node without involve-
ment of adjacent structures, suggestive of lymphoma (Fig. 1A 
and B). The 18-FDGPET/CT showed two hypermetabolic 
masses, corresponding to those described on CT, with mul-
tiple retroperitoneal and right iliac hypermetabolic lymph 
nodes (Fig. 2). A laparoscopic excisional-biopsy of the main 
mass was performed to confirm the suspicion of lymphoma 
diagnosis. Macroscopically, an encapsulated nodular mass 
measuring 8.5 × 5.5 × 5.5 cm was identified. Histopathologic 
assessment of the resected specimen showed clusters of small 
lymphocytes and epithelioid cells with eosinophilic cytoplasm 
and indistinct borders (Fig. 3A). We note sheets of ovoid 
cells with vesicular nuclei and pale eosinophilic cytoplasm. 
We note also mitotic activity, syncitial appearance, and the 
presence of interspersed lymphocytes (Fig. 3B). Immuno-
histochemical staining showed cells that were strongly posi-
tive for the FDCS marker CD23 (Fig. 3C) and negative for 
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four cycles (Fig. 4A), and a complete metabolic and radiologic 
response at the end of the first line (Fig. 4B and C). At nine 
months, recurrence was noted in the peripancreatic region on 
18-FDGPET/CT. She was further treated by a second line 
chemotherapy with etoposide, cisplatine, ARA-C, and pred-
nisone (ESHAP). The 18-FDGPET/CT performed after four 
courses showed a complete metabolic response. She received 
one more course of ESHAP followed by a bone marrow 
allotransplantation (BHS2 protocol). BHS2 is the reduced 
intensity conditioning regimen received by the patient con-
sisted in (total lymphoid irradiations) TLI 8 Gy (80c Gy/day 
during 10 days) from day-11 to day-7 and from day-4 to day-0, 
and rabbit ATG (Thymoglobulin Genzyme) 1.5 mg/kg/day 
during five days from day-11 to day−7. GVHD prophylaxis 
consisted in cyclosporine (Neoral), six months post transplan-
tation and mycophenolate mofetil acid, 1 gr bid (CellCept) 
during 45 days.21
At 24 months (eight months after bone marrow allotrans-
plantation), another recurrence occurred at the same site on 
18-FDGPET/CT. The patient received two lymphocytes 
infusions, from her previous donor, without therapeutic effec-
tiveness. Then, we proceeded by administration of a third line 
chemotherapy with gemcitabine, navelbine, and dexametha-
sone. The 18-FDGPET/CT performed after four courses 
showed a partial metabolic response. She received two addi-
tional courses in consolidation.
18-FDGPET/CT performed after six courses showed a 
complete metabolic response.
At the 29-month follow-up, she presented with a com-
plete metabolic response.
discussion
FDCS belong to dendritic cell sarcoma group with 
interdigitating dendritic cell sarcoma (IDCS) and fibroblastic 
reticular cell tumor (FRCT).
Figure 1. (A) homogenous enhancing mass in the lesser omentum 
located in front of the pancreas. (B) heterogeneous enhancing mass 
located below the liver.
Figure 2. Pre-chemotherapy 18-FdgPet/Ct showing multiple 
retroperitoneal and intra-abdominal infiltrations.
CD20, S-100-protein, and CD1a. ALK was also negative. 
No monoclonal rearrangement of the T-cell receptor gamma-
chain, of immunoglobulin heavy-chain gene or of immuno-
globulin kappa light-chain gene was revealed by PCR. These 
findings were considered diagnostic of FDCS. Multidisci-
plinary discussion of the case agreed on a classical lymphoma-
based chemotherapy with cyclophosphamide, adriamycin, 
vincristine, and prednisone (CHOP, six courses).
The patient received six courses of chemotherapy. 
A post-chemotherapeutic 18-FDGPET/CT performed six 
months after diagnosis showed a partial metabolic response 
and a macroscopic mass was still visible on CT after the first 
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Figure 3. (A) Clusters of small lymphocytes and epithelioid cells with 
eosinophilic cytoplasm and indistinct borders. (B) sheets of ovoid 
cells with vesicular nuclei and pale eosinophilic cytoplasm. note the 
mitotic activity, syncitial appearance, and the presence of interspersed 
lymphocytes. (C) Cd23 immunostaining, × 40.
Figure 4. (A) Residual mass after the first four cycles. (B) Post-
chemotherapy (first line) 18-FDGPET/CT showing complete metabolic 
response. (C) Complete radiologic response at the end of the first line of 
chemotherapy.
FDCS is a very rare neoplasm of antigen presenting cells 
of the B-cell follicles of lymphoid organs. FDCS affects mainly 
young adults without gender predilection.2 Recurrence is fre-
quent with local recurrence and distant metastases reported in 
about 40% of patients.3 FDCS are probably underdiagnosed 
because of its rarity and uncommon histological features. 
At histology, differential diagnoses are thymoma-like, men-
ingioma-like tumors and malignant fibrous histiocytoma. 
Immunohistochemical analyses are fundamental to confirm 
the diagnosis. Tumor cells show phenotype of non neoplastic 
follicular dendritic cells and are thus positive for markers 
CD21, CD23, and CD35.2–4 In addition, they are usually 
positive for desmoplakin, vimentin, fascin, and HLA-DR. 
Tumors cells are variably positive for S-100-protein and 
CD68 and they are consistently negative for CD1a, lysozyme, 
myeloperoxidase, CD34, CD3, CD79a, CD30, HMB-45, 
and cytokeratins. Most of the cases reported in the literature 
have involved lymph nodes of the neck, mediastinum, and 
axilla. Approximately one third of the cases were located in 
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extranodal sites, such as liver, tonsil, and intra-abdominal soft 
tissue.4–8,13 Intra-abdominal location is associated with higher 
recurrence, metastasis, or mortality rate.2,3,13
A recent literature review by Saygin et al reported 343 
published cases of FDCS but no specific data are reported on 
intra-abdominal disease.18
Etiopathogenesis of FDCS remains unclear. A stromal 
cell derivation origin and a hematopoietic lineage origin have 
been proposed. Hwang So et al have reported a transforma-
tion of Castleman disease into an intra-abdominal FDCS.19
Table 1 shows the clinical features of the 17 cases of intra 
abdominal FDCS reported so far.2–12,14,15 Complete surgi-
cal excision is mainly proposed for FDCS, but also for local 
resectable disease. According to small series and reviews, 
chemotherapy and radiotherapy have not yet proven their 
effectiveness for the treatment of FDCS.2,3,18,20 In the pres-
ent case, the perigastric mass did not seem completely resect-
able and there was retroperitoneal lymph node involvement. 
The disease was considered locally advanced. Advanced intra-
peritoneal FDCS is a very severe condition where treatment 
options are not well established.
Since curative surgery was not possible for this patient, 
we opted for a medical treatment with cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP) chemo-
therapy (identical protocol as used for aggressive lymphomas). 
The choice of this regimen in our case was based on a 
literature review where the association of cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP) was widely 
used and showed its efficacy.13 Other chemotherapeutic such 
as ICE (ifosfamid, carboplatin, etoposide), CHEOP, and 
ABVD (adriamycin, bleomycin, vincristine, dacarbazine) 
regi men have also been proposed.14
Given the bad prognosis of the disease, the recurrence 
after conventional chemotherapy and the availability of a 
familial donor, an allogeneic hematopoietic stem cell trans-
plantation (HSCT) was decided following the report of a sim-
ilar case in the literature.17 No rituximab was added because of 
the negativity of CD20. Even though a macroscopic mass was 
still in place after four cycles of chemotherapy, with reduced 
FDG capitation, a complete metabolic and radiologic response 
was achieved after six courses of chemotherapy. This obser-
vation suggests that chemotherapy can be effective in locally 
advanced FDCS. Longer follow-up and further cases are 
definitely needed in order to draw any conclusion. However, 
six courses of CHOP chemotherapy might be considered an 
option for patients with unresectable FDCS lesions.
table 1. Clinical features of intra abdominal FdCs reported in the literature.
RepoRteD CASeS SIte oF tuMoR InItIAL tReAtMent CheMotheRApY Agent outCoMe
Perez-Ordoñez et al.4 spleen Resection none Unknown
Peripancreatic tissue Resection none Unknown
loo12 intra abdominal Resection none Unknown
han et al.5 submucosal of the stomach Resection none disease free at 10 months
hollowood et al.6 small intestine Resection none Recurrence at 6 months
head of pancreas Resection none disease free at 4 months
Chan et al.2 Wall of small intestine Resection of small bowel none Recurrence at 6 months
head of pancreas subtotal resection none died at 11 months
de Pas et al.3 liver Cholecystectomy-liver  
resection
none Recurrence at 11 months
skarin a10 anterior abdominal wall Resection followed by  
radiotherapy
none disease free at 8 months
Chan et al.2 Mesocolon and mesenteric  
lymph nodes
debulking resection  
followed by chemotherapy
Protocol as used for aggressive  
lymphomas
(no details)
Recurrence at 18 months
sander et al.7 spleen Resection followed by  
chemotherapy
adriamycin, isofosfamide, gCsFa died at 9 months
yamakawa11 Omentum Resection followed by  
chemotherapy
ChOPb died at 30 months
geerts et al.8 stomach and liver metastasis Unknown Unknown Unknown
Chien-Feng9 Multiple abdominal tumors Unknown Unknown Unknown
Chien Jerry et al.19 Omentum Resection Unknown Unknown
hwang soon et al.18 Pancreas Resection none (Radiation alone) disease free at 9 months




disease free at 29 months
notes: agranulocyte colony-stimulating factor. bCyclophosphamide, adriamycin, vincristin sulfate and prednisolone. cetoposide, Cisplatine, aRa-C and Prednisone.
dgemcitabine, navelbine, dexamethasone.
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Conclusion
FDCS is a rare entity, especially those located in the intra-
peritoneal cavity. The diagnosis must be kept in mind when 
confronted with uncommon histological features in lymphoid 
tissue. A complete metabolic response after six courses of 
CHOP was achieved in a patient with FDCS. Even though 
complete excision is currently known to be the best way to 
treat early stage FDCS, our case confirms other reports’ sug-
gestion that ‘lymphoma-like’ chemotherapy could be a good 
option in patients with advanced unresectable disease.
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